A new study published in Antiviral Research suggests that a class of antiviral drugs called Pin1 inhibitors could significantly reduce or even stop outbreaks of herpes simplex virus 1 (HSV-1) — the virus responsible for oral herpes. HSV-1, known for causing cold sores and fever blisters, affects nearly 50% to 90% of people worldwide. After the first infection, the virus stays dormant in the body but can reactivate periodically. Although most infections are mild, HSV-1 can be dangerous or even fatal for individuals with weakened immune systems. Therefore, identifying more effective antiviral therapies is crucial.
Targeting a Key Enzyme: Pin1
The research focused on peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1), an enzyme that plays a major role in regulating protein stability, cell function, and structure. When dysregulated, Pin1 is linked to multiple diseases, including cancer, obesity, and heart failure. Previous studies have also shown that viruses like cytomegalovirus (CMV) and SARS-CoV-2 interact with and exploit this enzyme. Scientists have already developed Pin1 inhibitors to counter the effects of these viruses.
Because HSV-infected cells overexpress Pin1, researchers at Hiroshima University investigated whether inhibiting this enzyme could also stop HSV-1. “This study revealed that the host factor Pin1 is a crucial therapeutic target for the proliferation of HSV-1. Pin1 inhibitors potently suppress HSV-1 replication at low concentrations,” said Professor Takemasa Sakaguchi, lead researcher from the Graduate School of Biomedical and Health Sciences.
Laboratory Results Show Strong Antiviral Effects
In laboratory experiments, researchers tested H-77 and four newly developed Pin1 inhibitors on VeroE6 cells, a standard cell line used in virology. When these infected cells were treated with increasing concentrations of the inhibitors, HSV-1 activity declined sharply. At a concentration of 1 μM, viral effects disappeared entirely, and the few viral particles released were found to be non-infectious.
As reported by medicalxpress, these findings indicate that Pin1 inhibitors do more than stop viral replication — they disrupt the virus’s ability to escape from host cells.
How Pin1 Inhibitors Trap the Virus
The study uncovered a remarkable mechanism behind this antiviral effect. Pin1 inhibitors strengthen the nuclear membrane, forming a reinforced barrier that traps the virus inside the cell nucleus. Under normal circumstances, HSV-1 overexpresses Pin1 to weaken this barrier, allowing the virus to escape. However, the inhibitor H-77 reverses this process.
“The nuclear lamina initially acts as a barrier when progeny viruses bud from the nuclear membrane. Pin1 overexpressed by the virus removes this barrier,” explained Sakaguchi. “Through the action of the Pin1 inhibitor H-77, this barrier becomes thicker and stronger — essentially forming an impregnable defensive wall that prevents viral escape.”
Toward Host-Directed Antiviral Therapies
Moving forward, the research team plans to evaluate Pin1 inhibitors against other viruses and refine the compounds to improve their potency and selectivity. The goal is to develop host-directed therapeutics — drugs that target host cell factors rather than viral components, thereby minimizing the risk of drug resistance.
“The ultimate goal for the future is to achieve the clinical application of Pin1 inhibitors as host-directed therapeutics,” Sakaguchi added. “To do this, we will first assess their effectiveness across different viruses and then optimize the compound structure to create stronger and more selective drugs.”
Summary
This breakthrough study highlights the potential of Pin1 inhibitors as a new class of antivirals capable of blocking HSV-1 replication and spread. By reinforcing the nuclear membrane, these compounds could revolutionize herpes treatment — and possibly offer new hope against other viral infections as well.